Literature DB >> 19748501

MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females.

Natasa Karas-Kuzelicki1, Miha Milek, Irena Mlinaric-Rascan.   

Abstract

OBJECTIVES: TPMT catalyzes the deactivation of the cytostatic drug 6-mercaptopurine used in treatment of cancer. Patients with low levels of TPMT more often experience severe toxic effects when treated with standard doses of 6-mercaptopurine than patients with high levels who, in turn, may experience inadequate treatment. It is therefore very important to assess factors that could influence TPMT activity. DESIGN AND METHODS: Red blood cell TPMT activity was measured by means of HPLC and genotypes of 86 healthy individuals were analyzed using TaqMan and PCR-RFLP methods, in order to investigate the effect of TPMT, MTHFR and TYMS genotypes on TPMT activity.
RESULTS: TPMT activity was higher in TPMT wild-type males than females (p=0.028). Three-way ANOVA interaction analysis revealed a significant interaction effect between MTHFR genotype and gender on TPMT activity (p=0.023).
CONCLUSION: Males have higher TPMT activity than females and the trend of influence of MTHFR genotype on TPMT activity is different in the two gender groups. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748501     DOI: 10.1016/j.clinbiochem.2009.09.003

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Clinical predictors of thiopurine-related adverse events in Crohn's disease.

Authors:  Gordon W Moran; Marie-France Dubeau; Gilaad G Kaplan; Hong Yang; Bertus Eksteen; Subrata Ghosh; Remo Panaccione
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.

Authors:  Ravi Ramalingam; Harpreet Kaur; Julius Xavier Scott; Latha M Sneha; Ganeshprasad Arunkumar; Arathi Srinivasan; Solomon F D Paul
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-14       Impact factor: 3.333

3.  Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.

Authors:  E W Chua; S Cree; M L Barclay; K Doudney; K Lehnert; A Aitchison; M A Kennedy
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

4.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 5.  [Research advances in pharmacogenomics of mercaptopurine].

Authors:  Xiao-Xiao Chen; Shu-Hong Shen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-09

Review 6.  Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.

Authors:  Yoichi Kakuta; Yoshitaka Kinouchi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2017-11-30       Impact factor: 7.527

Review 7.  Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.

Authors:  Sheng Zhang Lim; Eng Wee Chua
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810

Review 8.  Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.

Authors:  Sonja Pavlovic; Nikola Kotur; Biljana Stankovic; Branka Zukic; Vladimir Gasic; Lidija Dokmanovic
Journal:  Genes (Basel)       Date:  2019-03-01       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.